SEARCH

SEARCH BY CITATION

References

  • 1
    UNAIDS: Report on AIDS Epidemic. July 2008.
  • 2
    Hladik F, McElrath MJ: Setting the stage: host invasion by HIV. Nat Rev Immunol 2008; 8:447457.
  • 3
    Wira CR, Fahey JV, Sentman CL, Pioli PA, Shen L: Innate and adaptive immunity in female genital tract: cellular responses and interactions. Immunol Rev 2005; 206:306335.
  • 4
    Norvell MK, Benrubi GI, Thompson RJ: Investigation of microtrauma after sexual intercourse. J Reprod Med 1984; 29:269271.
  • 5
    Guimaraes MD, Vlahov D, Castilho EA: Postcoital vaginal bleeding as a risk factor for transmission of the human immunodeficiency virus in a heterosexual partner study in Brazil. Rio de Janeiro Heterosexual Study Group. Arch Intern Med 1997; 157:13621368.
  • 6
    Cohen MS and Anderson DJ: Genitourinary mucosal defenses. In Sexually Transmitted Diseases, KKHolmes, PFSparling, PAMardh, SMLemon, WEStamm, PPiot, JNWasserheit (eds). New York, McGraw-Hill, 1999, pp. 173190.
  • 7
    Lai SK, Hida K, Shukair S, Wang YY, Figueiredo A, Cone R, Hope TJ, Hanes J: Human immunodeficiency virus type 1 is trapped by acidic but not by neutralized human cervicovaginal mucus. J Virol 2009; 83:1119611200.
  • 8
    King AE, Critchley HO, Kelly RW: Presence of secretory leukocyte protease inhibitor in human endometrium and first trimester decidua suggests an antibacterial protective role. Mol Hum Reprod 2000; 6:191196.
  • 9
    Casslen B, Rosengren M, Ohlsson K: Localization and quantitation of a low molecular weight proteinase inhibitor, antileukoprotease, in the human uterus. Hoppe Seylers Z Physiol Chem 1981; 362:953961.
  • 10
    Wahl SM, McNeely TB, Janoff EN, Shugars D, Worley P, Tucker C, Orenstein JM: Secretory leukocyte protease inhibitor (SLPI) in mucosal fluids inhibits HIV-I. Oral Dis 1997; 3(Suppl. 1):S64S69.
  • 11
    McNeely TB, Dealy M, Dripps DJ, Orenstein JM, Eisenberg SP, Wahl SM: Secretory leukocyte protease inhibitor: a human saliva protein exhibiting anti-human immunodeficiency virus 1 activity in vitro. J Clin Invest 1995; 96:456464.
  • 12
    McNeely TB, Shugars DC, Rosendahl M, Tucker C, Eisenberg SP, Wahl SM: Inhibition of human immunodeficiency virus type 1 infectivity by secretory leukocyte protease inhibitor occurs prior to viral reverse transcription. Blood 1997; 90:11411149.
  • 13
    Harmsen MC, Swart PJ, De Bethune MP, Pauwels R, De Clercq E, The TH, Meijer DK: Antiviral effects of plasma and milk proteins: lactoferrin shows potent activity against both human immunodeficiency virus and human cytomegalovirus replication in vitro. J Infect Dis 1995; 172:380388.
  • 14
    Moriuchi M, Moriuchi H: A milk protein lactoferrin enhances human T cell leukemia virus type I and suppresses HIV-1 infection. J Immunol 2001; 166:42314236.
  • 15
    Janeway Jr CA, Medzhitov R: Innate immune recognition. Annu Rev Immunol 2002; 20:197216.
  • 16
    Klotman ME, Chang TL: Defensins in innate antiviral immunity. Nat Rev Immunol 2006; 6:447456.
  • 17
    Ganz T: Defensins: antimicrobial peptides of innate immunity. Nat Rev Immunol 2003; 3:710720.
  • 18
    Leonova L, Kokryakov VN, Aleshina G, Hong T, Nguyen T, Zhao C, Waring AJ, Lehrer RI: Circular minidefensins and posttranslational generation of molecular diversity. J Leukoc Biol 2001; 70:461464.
  • 19
    Quinones-Mateu ME, Lederman MM, Feng Z, Chakraborty B, Weber J, Rangel HR, Marotta ML, Mirza M, Jiang B, Kiser P, Medvik K, Sieg SF, Weinberg A: Human epithelial beta-defensins 2 and 3 inhibit HIV-1 replication. AIDS 2003; 17:F39F48.
  • 20
    Sun L, Finnegan CM, Kish-Catalone T, Blumenthal R, Garzino-Demo P, La Terra Maggiore GM, Berrone S, Kleinman C, Wu Z, Abdelwahab S, Lu W, Garzino-Demo A: Human beta-defensins suppress human immunodeficiency virus infection: potential role in mucosal protection. J Virol 2005; 79:1431814329.
  • 21
    Iqbal SM, Ball TB, Levinson P, Maranan L, Jaoko W, Wachihi C, Pak BJ, Podust VN, Broliden K, Hirbod T, Kaul R, Plummer FA: Elevated elafin/trappin-2 in the female genital tract is associated with protection against HIV acquisition. AIDS 2009; 23:16691677.
  • 22
    Ghosh M, Shen Z, Fahey JV, Cu-Uvin S, Mayer K, Wira CR: Trappin-2/Elafin: a novel innate anti-human immunodeficiency virus-1 molecule of the human female reproductive tract. Immunology 2009; 129:207219.
  • 23
    Chen K, Huang J, Zhang C, Huang S, Nunnari G, Wang FX, Tong X, Gao L, Nikisher K, Zhang H: Alpha interferon potently enhances the anti-human immunodeficiency virus type 1 activity of APOBEC3G in resting primary CD4 T cells. J Virol 2006; 80: 76457657.
  • 24
    Cremer I, Vieillard V, De Maeyer E: Retrovirally mediated IFN-beta transduction of macrophages induces resistance to HIV, correlated with up-regulation of RANTES production and down-regulation of C-C chemokine receptor-5 expression. J Immunol 2000; 164:15821587.
  • 25
    Zhou A, Hassel BA, Silverman RH: Expression cloning of 2-5A-dependent RNAase: a uniquely regulated mediator of interferon action. Cell 1993; 72:753765.
  • 26
    Clemens MJ, Williams BR: Inhibition of cell-free protein synthesis by pppA2’p5’A2’p5’A: a novel oligonucleotide synthesized by interferon-treated L cell extracts. Cell 1978; 13:565572.
  • 27
    Player MR, Maitra RK, Silverman RH, Torrence PF: Targeting RNase L to human immunodeficiency virus RNA with 2-5A-antisense. Antivir Chem Chemother 1998; 9:225231.
  • 28
    Sobol RW, Fisher WL, Reichenbach NL, Kumar A, Beard WA, Wilson SH, Charubala R, Pfleiderer W, Suhadolnik RJ: HIV-1 reverse transcriptase: inhibition by 2′,5′-oligoadenylates. Biochemistry 1993; 32: 1211212118.
  • 29
    Karpov AV: Endogenous and exogenous interferons in HIV-infection. Eur J Med Res 2001; 6:507524.
  • 30
    Dhawan S, Heredia A, Wahl LM, Epstein JS, Meltzer MS, Hewlett IK: Interferon-gamma-induced downregulation of CD4 inhibits the entry of human immunodeficiency virus type-1 in primary monocytes. Pathobiology 1995; 63:9399.
  • 31
    Dhawan S, Wahl LM, Heredia A, Zhang Y, Epstein JS, Meltzer MS, Hewlett IK: Interferon-gamma inhibits HIV-induced invasiveness of monocytes. J Leukoc Biol 1995; 58:713716.
  • 32
    Hariharan D, Douglas SD, Lee B, Lai JP, Campbell DE, Ho WZ: Interferon-gamma upregulates CCR5 expression in cord and adult blood mononuclear phagocytes. Blood 1999; 93:11371144.
  • 33
    Biswas P, Poli G, Kinter AL, Justement JS, Stanley SK, Maury WJ, Bressler P, Orenstein JM, Fauci AS: Interferon gamma induces the expression of human immunodeficiency virus in persistently infected promonocytic cells (U1) and redirects the production of virions to intracytoplasmic vacuoles in phorbol myristate acetate-differentiated U1 cells. J Exp Med 1992; 176:739750.
  • 34
    Han X, Becker K, Degen HJ, Jablonowski H, Strohmeyer G: Synergistic stimulatory effects of tumour necrosis factor alpha and interferon gamma on replication of human immunodeficiency virus type 1 and on apoptosis of HIV-1-infected host cells. Eur J Clin Invest 1996; 26:286292.
  • 35
    Hou W, Wang X, Ye L, Zhou L, Yang ZQ, Riedel E, Ho WZ: Lambda interferon inhibits human immunodeficiency virus type 1 infection of macrophages. J Virol 2009; 83:38343842.
  • 36
    Schaefer TM, Desouza K, Fahey JV, Beagley KW, Wira CR: Toll-like receptor (TLR) expression and TLR-mediated cytokine/chemokine production by human uterine epithelial cells. Immunology 2004; 112: 428436.
  • 37
    Baggiolini M: Activation and recruitment of neutrophil leukocytes. Clin Exp Immunol 1995; 101(Suppl. 1):56.
  • 38
    Yoshimura T, Leonard EJ: Human monocyte chemoattractant protein-1: structure and function. Cytokines 1992; 4:131152.
  • 39
    Agace WW, Amara A, Roberts AI, Pablos JL, Thelen S, Uguccioni M, Li XY, Marsal J, Arenzana-Seisdedos F, Delaunay T, Ebert EC, Moser B, Parker CM: Constitutive expression of stromal derived factor-1 by mucosal epithelia and its role in HIV transmission and propagation. Curr Biol 2000; 10:325328.
  • 40
    Cocchi F, DeVico AL, Garzino-Demo A, Arya SK, Gallo RC, Lusso P: Identification of RANTES, MIP-1 alpha, and MIP-1 beta as the major HIV-suppressive factors produced by CD8+ T cells. Science 1995; 270:18111815.
  • 41
    Abdelwahab SF, Cocchi F, Bagley KC, Kamin-Lewis R, Gallo RC, DeVico A, Lewis GK: HIV-1-suppressive factors are secreted by CD4+ T cells during primary immune responses. Proc Natl Acad Sci USA 2003; 100:1500615010.
  • 42
    Fahey JV, Schaefer TM, Channon JY, Wira CR: Secretion of cytokines and chemokines by polarized human epithelial cells from the female reproductive tract. Hum Reprod 2005; 20:14391446.
  • 43
    Nazli A, Yao XD, Smieja M, Rosenthal KL, Ashkar AA, Kaushic C: Differential induction of innate anti-viral responses by TLR ligands against Herpes simplex virus, type 2, infection in primary genital epithelium of women. Antiviral Res 2009; 81:103112.
  • 44
    Harwani SC, Lurain NS, Zariffard MR, Spear GT: Differential inhibition of human cytomegalovirus (HCMV) by toll-like receptor ligands mediated by interferon-beta in human foreskin fibroblasts and cervical tissue. Virol J 2007; 4:133.
  • 45
    Howell AL, Edkins RD, Rier SE, Yeaman GR, Stern JE, Fanger MW, Wira CR: Human immunodeficiency virus type 1 infection of cells and tissues from the upper and lower human female reproductive tract. J Virol 1997; 71:34983506.
  • 46
    Bomsel M: Transcytosis of infectious human immunodeficiency virus across a tight human epithelial cell line barrier. Nat Med 1997; 3:4247.
  • 47
    Bobardt MD, Chatterji U, Selvarajah S, Van der Schueren B, David G, Kahn B, Gallay PA: Cell-free human immunodeficiency virus type 1 transcytosis through primary genital epithelial cells. J Virol 2007; 81:395405.
  • 48
    Saidi H, Magri G, Nasreddine N, Requena M, Belec L: R5- and X4-HIV-1 use differentially the endometrial epithelial cells HEC-1A to ensure their own spread: implication for mechanisms of sexual transmission. Virology 2007; 358:5568.
  • 49
    Dezzutti CS, Guenthner PC, Cummins Jr JE, Cabrera T, Marshall JH, Dillberger A, Lal RB: Cervical and prostate primary epithelial cells are not productively infected but sequester human immunodeficiency virus type 1. J Infect Dis 2001; 183:12041213.
  • 50
    Wu Z, Chen Z, Phillips DM: Human genital epithelial cells capture cell-free human immunodeficiency virus type 1 and transmit the virus to CD4+ Cells: implications for mechanisms of sexual transmission. J Infect Dis 2003; 188:14731482.
  • 51
    Berlier W, Bourlet T, Lawrence P, Hamzeh H, Lambert C, Genin C, Verrier B, Dieu-Nosjean MC, Pozzetto B, Delezay O: Selective sequestration of X4 isolates by human genital epithelial cells: implication for virus tropism selection process during sexual transmission of HIV. J Med Virol 2005; 77:465474.
  • 52
    Yeaman GR, Asin S, Weldon S, Demian DJ, Collins JE, Gonzalez JL, Wira CR, Fanger MW, Howell AL: Chemokine receptor expression in the human ectocervix: implications for infection by the human immunodeficiency virus-type I. Immunology 2004; 113:524533.
  • 53
    Furuta Y, Eriksson K, Svennerholm B, Fredman P, Horal P, Jeansson S, Vahlne A, Holmgren J, Czerkinsky C: Infection of vaginal and colonic epithelial cells by the human immunodeficiency virus type 1 is neutralized by antibodies raised against conserved epitopes in the envelope glycoprotein gp120. Proc Natl Acad Sci USA 1994; 91:1255912563.
  • 54
    Stoddard E, Cannon G, Ni H, Kariko K, Capodici J, Malamud D, Weissman D: gp340 expressed on human genital epithelia binds HIV-1 envelope protein and facilitates viral transmission. J Immunol 2007; 179:31263132.
  • 55
    Stoddard E, Ni H, Cannon G, Zhou C, Kallenbach N, Malamud D, Weissman D: gp340 promotes transcytosis of human immunodeficiency virus type 1 in genital tract-derived cell lines and primary endocervical tissue. J Virol 2009; 83:85968603.
  • 56
    Hu J, Gardner MB, Miller CJ: Simian immunodeficiency virus rapidly penetrates the cervicovaginal mucosa after intravaginal inoculation and infects intraepithelial dendritic cells. J Virol 2000; 74:60876095.
  • 57
    Hladik F, Sakchalathorn P, Ballweber L, Lentz G, Fialkow M, Eschenbach D, McElrath MJ: Initial events in establishing vaginal entry and infection by human immunodeficiency virus type-1. Immunity 2007; 26:257270.
  • 58
    Bouschbacher M, Bomsel M, Verronese E, Gofflo S, Ganor Y, Dezutter-Dambuyant C, Valladeau J: Early events in HIV transmission through a human reconstructed vaginal mucosa. AIDS 2008; 22: 12571266.
  • 59
    Pudney J, Quayle AJ, Anderson DJ: Immunological microenvironments in the human vagina and cervix: mediators of cellular immunity are concentrated in the cervical transformation zone. Biol Reprod 2005; 73:12531263.
  • 60
    Nazli A, Chan O, Dobson-Belaire WN, Ouellet M, Tremblay MJ, Gray-Owen SD, Arsenault AL and Kaushic C: Exposure to HIV-1 directly impairs mucosal epithelial barrier integrity allowing microbial translocation. PLoS Pathog 2010; 6: DOI: 10.1371/journal.ppat.1000852.
  • 61
    Population Division UNDoEaSA: World Contraceptive Use 2003. In, 2003.
  • 62
    Baeten JM, Lavreys L, Sagar M, Kreiss JK, Richardson BA, Chohan B, Panteleeff D, Mandaliya K, Ndinya-Achola JO, Overbaugh J, Farley T, Mwachari C, Cohen C, Chipato T, Jaisamrarn U, Kiriwat O, Duerr A: Effect of contraceptive methods on natural history of HIV: studies from the Mombasa cohort. J Acquir Immune Defic Syndr 2005; 38(Suppl. 1):S18S21.
  • 63
    Stringer E, Antonsen E: Hormonal contraception and HIV disease progression. Clin Infect Dis 2008; 47: 945951.
  • 64
    Marx PA, Spira AI, Gettie A, Dailey PJ, Veazey RS, Lackner AA, Mahoney CJ, Miller CJ, Claypool LE, Ho DD, Alexander NJ: Progesterone implants enhance SIV vaginal transmission and early virus load. Nat Med 1996; 2:10841089.
  • 65
    Stringer EM, Kaseba C, Levy J, Sinkala M, Goldenberg RL, Chi BH, Matongo I, Vermund SH, Mwanahamuntu M, Stringer JS: A randomized trial of the intrauterine contraceptive device vs hormonal contraception in women who are infected with the human immunodeficiency virus. Am J Obstet Gynecol 2007; 197:144 e141144 e148.
  • 66
    Fish EN: The X-files in immunity: sex-based differences predispose immune responses. Nat Rev Immunol 2008; 8:737744.
  • 67
    White HD, Crassi KM, Givan AL, Stern JE, Gonzalez JL, Memoli VA, Green WR, Wira CR: CD3+ CD8+ CTL activity within the human female reproductive tract: influence of stage of the menstrual cycle and menopause. J Immunol 1997; 158:30173027.
  • 68
    Hao S, Zhao J, Zhou J, Zhao S, Hu Y, Hou Y: Modulation of 17beta-estradiol on the number and cytotoxicity of NK cells in vivo related to MCM and activating receptors. Int Immunopharmacol 2007; 7:17651775.
  • 69
    Hel Z, Stringer E, Mestecky J: Sex Steroid Hormones, Hormonal Contraception, and the Immunobiology of Human Immunodeficiency Virus-1 Infection. Endocr Rev 2009; 31:7997.
  • 70
    Baeten JM, Lavreys L, Overbaugh J: The influence of hormonal contraceptive use on HIV-1 transmission and disease progression. Clin Infect Dis 2007; 45: 360369.
  • 71
    Smith SM, Mefford M, Sodora D, Klase Z, Singh M, Alexander N, Hess D, Marx PA: Topical estrogen protects against SIV vaginal transmission without evidence of systemic effect. AIDS 2004; 18:16371643.
  • 72
    Smith SM, Baskin GB, Marx PA: Estrogen protects against vaginal transmission of simian immunodeficiency virus. J Infect Dis 2000; 182: 708715.
  • 73
    Kiddugavu M, Makumbi F, Wawer MJ, Serwadda D, Sewankambo NK, Wabwire-Mangen F, Lutalo T, Meehan M, Xianbin , Gray RH: Hormonal contraceptive use and HIV-1 infection in a population-based cohort in Rakai, Uganda. AIDS 2003; 17:233240.
  • 74
    Myer L, Denny L, Wright TC, Kuhn L: Prospective study of hormonal contraception and women’s risk of HIV infection in South Africa. Int J Epidemiol 2007; 36:166174.
  • 75
    Bulterys M, Smith D, Chao A, Jaffe H: Hormonal contraception and incident HIV-1 infection: new insight and continuing challenges. AIDS 2007; 21:9799.
  • 76
    Morrison CS, Richardson BA, Mmiro F, Chipato T, Celentano DD, Luoto J, Mugerwa R, Padian N, Rugpao S, Brown JM, Cornelisse P, Salata RA: Hormonal contraception and the risk of HIV acquisition. AIDS 2007; 21:8595.
  • 77
    Kaushic C, Ashkar AA, Reid LA, Rosenthal KL: Progesterone increases susceptibility and decreases immune responses to genital herpes infection. J Virol 2003; 77:45584565.
  • 78
    Gillgrass AE, Ashkar AA, Rosenthal KL, Kaushic C: Prolonged exposure to progesterone prevents induction of protective mucosal responses following intravaginal immunization with attenuated herpes simplex virus type 2. J Virol 2003; 77:98459851.
  • 79
    Gillgrass AE, Fernandez SA, Rosenthal KL, Kaushic C: Estradiol regulates susceptibility following primary exposure to genital herpes simplex virus type 2, while progesterone induces inflammation. J Virol 2005; 79:31073116.
  • 80
    Gillgrass AE, Tang VA, Towarnicki KM, Rosenthal KL, Kaushic C: Protection against genital herpes infection in mice immunized under different hormonal conditions correlates with induction of vagina-associated lymphoid tissue. J Virol 2005; 79: 31173126.
  • 81
    Bhavanam S, Snider DP, Kaushic C: Intranasal and subcutaneous immunization under the effect of estradiol leads to better protection against genital HSV-2 challenge compared to progesterone. Vaccine 2008; 26:61656172.
  • 82
    Pennock JW, Stegall R, Bell B, Vargas G, Motamedi M, Milligan G, Bourne N: Estradiol improves genital herpes vaccine efficacy in mice. Vaccine 2009; 27:58305836.
  • 83
    Corbett EL, Steketee RW, Ter Kuile FO, Latif AS, Kamali A, Hayes RJ: HIV-1/AIDS and the control of other infectious diseases in Africa. Lancet 2002; 359:21772187.
  • 84
    Iqbal SM, Kaul R: Mucosal innate immunity as a determinant of HIV susceptibility. Am J Reprod Immunol 2008; 59:4454.
  • 85
    Rotchford K, Strum AW, Wilkinson D: Effect of coinfection with STDs and of STD treatment on HIV shedding in genital-tract secretions: systematic review and data synthesis. Sex Transm Dis 2000; 27:243248.
  • 86
    Johnson LF, Lewis DA: The effect of genital tract infections on HIV-1 shedding in the genital tract: a systematic review and meta-analysis. Sex Transm Dis 2008; 35:946959.
  • 87
    Plummer FA: Heterosexual transmission of human immunodeficiency virus type 1 (HIV): interactions of conventional sexually transmitted diseases, hormonal contraception and HIV-1. AIDS Res Hum Retroviruses 1998; 14(Suppl. 1):S5S10.
  • 88
    Corey L, Wald A, Celum CL, Quinn TC: The effects of herpes simplex virus-2 on HIV-1 acquisition and transmission: a review of two overlapping epidemics. J Acquir Immune Defic Syndr 2004; 35:435445.
  • 89
    Freeman EE, Weiss HA, Glynn JR, Cross PL, Whitworth JA, Hayes RJ: Herpes simplex virus 2 infection increases HIV acquisition in men and women: systematic review and meta-analysis of longitudinal studies. AIDS 2006; 20:7383.
  • 90
    Celum CL: The interaction between herpes simplex virus and human immunodeficiency virus. Herpes 2004; 11(Suppl. 1):36A45A.
  • 91
    Mole L, Ripich S, Margolis D, Holodniy M: The impact of active herpes simplex virus infection on human immunodeficiency virus load. J Infect Dis 1997; 176:766770.
  • 92
    McClelland RS, Wang CC, Overbaugh J, Richardson BA, Corey L, Ashley RL, Mandaliya K, Ndinya-Achola J, Bwayo JJ, Kreiss JK: Association between cervical shedding of herpes simplex virus and HIV-1. AIDS 2002; 16:24252430.
  • 93
    Zhu J, Hladik F, Woodward A, Klock A, Peng T, Johnston C, Remington M, Magaret A, Koelle DM, Wald A, Corey L: Persistence of HIV-1 receptor-positive cells after HSV-2 reactivation is a potential mechanism for increased HIV-1 acquisition. Nat Med 2009; 15:886892.
  • 94
    Koelle DM, Liu Z, McClurkan CM, Topp MS, Riddell SR, Pamer EG, Johnson AS, Wald A, Corey L: Expression of cutaneous lymphocyte-associated antigen by CD8(+) T cells specific for a skin-tropic virus. J Clin Invest 2002; 110:537548.
  • 95
    Margolis DM, Rabson AB, Straus SE, Ostrove JM: Transactivation of the HIV-1 LTR by HSV-1 immediate-early genes. Virology 1992; 186:788791.
  • 96
    Royce RA, Sena A, Cates Jr W, Cohen MS: Sexual transmission of HIV. N Engl J Med 1997; 336:10721078.
  • 97
    Munch J, Rucker E, Standker L, Adermann K, Goffinet C, Schindler M, Wildum S, Chinnadurai R, Rajan D, Specht A, Gimenez-Gallego G, Sanchez PC, Fowler DM, Koulov A, Kelly JW, Mothes W, Grivel JC, Margolis L, Keppler OT, Forssmann WG, Kirchhoff F: Semen-derived amyloid fibrils drastically enhance HIV infection. Cell 2007; 131:10591071.
  • 98
    Ronnberg L, Vihko P, Sajanti E, Vihko R: Clomiphene citrate administration to normogonadotropic subfertile men: blood hormone changes and activation of acid phosphatase in seminal fluid. Int J Androl 1981; 4:372378.
  • 99
    Berlier W, Cremel M, Hamzeh H, Levy R, Lucht F, Bourlet T, Pozzetto B, Delezay O: Seminal plasma promotes the attraction of Langerhans cells via the secretion of CCL20 by vaginal epithelial cells: involvement in the sexual transmission of HIV. Hum Reprod 2006; 21:11351142.
  • 100
    Bouhlal H, Chomont N, Haeffner-Cavaillon N, Kazatchkine MD, Belec L, Hocini H: Opsonization of HIV-1 by semen complement enhances infection of human epithelial cells. J Immunol 2002; 169: 33013306.
  • 101
    Gutsche S, Von Wolff M, Strowitzki T, Thaler CJ: Seminal plasma induces mRNA expression of IL-1beta, IL-6 and LIF in endometrial epithelial cells in vitro. Mol Hum Reprod 2003; 9:785791.
  • 102
    Sharkey DJ, Macpherson AM, Tremellen KP, Robertson SA: Seminal plasma differentially regulates inflammatory cytokine gene expression in human cervical and vaginal epithelial cells. Mol Hum Reprod 2007; 13:491501.
  • 103
    Robertson SA, Ingman WV, O’Leary S, Sharkey DJ, Tremellen KP: Transforming growth factor beta--a mediator of immune deviation in seminal plasma. J Reprod Immunol 2002; 57:109128.